Post

New research · Oncology
Medical sciences (Basel, Switzerland) · 1w
Cohort studyMedical sciences (Basel, Switzerland) · 2026

Cancer Risk in Clinically Recognized Celiac Disease: A Nationwide Propensity-Matched Cohort Study.

Reem Zabit, Ahmad Shibly, Jamal Zidan … Ismaell Massalha
Read paper
OncologyCohort study

Clinically recognized celiac disease is associated with a higher rate of invasive cancer

Cancer Risk in Clinically Recognized Celiac Disease: A Nationwide Propensity-Matched Cohort Study.

Reem Zabit … Ismaell Massalha
Medical sciences (Basel, Switzerland) · 2026
Background

Celiac disease (celiac disease) is common, but its cancer-risk profile remains incompletely defined.

Methods

We used longitudinal electronic health record (electronic health record) data from Clalit Health Services for a propensity-matched cohort.

n = 8143 individuals
Results

people with celiac disease developed invasive cancer more often than matched people without it

HR 1.68 (95% CI 1.31 to 2.14)
null 1
1.31
2.14
CI excludes the null - significant
More results

The primary matched cohort included 8143 individuals: 1006 with celiac disease and 7137 controls, contributing 49,330.5 person-years.

Strongest signals were hematological malignancy codes (HR 1.99), lymphoma codes (HR 1.90), and gastrointestinal (gastrointestinal) cancer codes (HR 2.71).

More results

Associations persisted after one-year and two-year lags.

In the dated-event sensitivity cohort (161 celiac disease; 1610 controls), celiac disease remained associated with invasive cancer (HR 1.68, 95% CI 1.31-2.14), with the strongest signals for lymphoma (HR 2.81) and gastrointestinal cancer (HR 2.25).

“
Conclusion · 1 of 2

In clinically recognized celiac disease, cancer hazard was elevated and category-specific, concentrated in hematological, lymphoid, and gastrointestinal codes with a gut-oriented T-cell lymphoma signal.

Conclusion · 2 of 2

The findings support targeted clinical vigilance, not expanded screening, and describe relative associations that require registry-linked confirmation.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
1.16%
Safety Agent gating reduced incorrect patient inclusion to 1.16% for non-small cell lung cancer trials.
Guideline
at least 20years
patients need this much follow-up because the cancer can come back many years later
AI / Informatics
32
studies exploring machine learning to predict cancer outcomes
Cohort Study
0.791
Automated whole-tumor outlines overlapped expert outlines fairly well (1.0 = perfect match)
Randomized Trial
hazard ratio 0·67
pirarubicin instillation led to a lower risk of recurrence compared to observation
Guideline
“As more new targeted agents become available and hypomethylating agent-based triplet combinations are used more widely, we fully anticipate that we will, in some years' time, write a fourth guideline on the management of AML in older patients.”
AI / Informatics
AUC = 0.939
This shows the model's excellent ability to predict ovarian cancer treatment response
Case Report
12 mm
the brain's center was pushed sideways due to severe swelling